专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

US20060051755A1 Methods of assaying for cell cycle modulators 审中-公开
标题翻译：测定细胞周期调节剂的方法
公开(公告)号：US20060051755A1
公开(公告)日：2006-03-09
申请号：US10510903
申请日：2003-04-15
申请人： Yasumichi Hitoshi , Yonchu Jenkins
发明人： Yasumichi Hitoshi , Yonchu Jenkins
IPC分类号： C12Q1/68
CPC分类号： G01N33/5091 , C12Q1/6886 , C12Q2600/158 , G01N33/5008 , G01N33/5011 , G01N33/574 , G01N33/6872 , G01N2333/4703 , G01N2500/00
摘要： The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding BRCA-1-Associated Protein-1 (BAP-1), Nuclear Protein 95 (NP95), Fanconi anemia group A protein (FANCA), DEAD/H box polypeptide 9 (DDX9), insulin-like growth factor 1 receptor (IGF1R), ubiquitin-conjugating enzyme E2 variant 1 (UBE2V1), aldehyde dehydrogenase, pyruvate kinase, glucose-6-phosphate dehydrogenase, HCDR-3, DEAD/H box polypeptide 21 (DDX21), serine threonine kinase 15 (ARK2), transmembrane 4 superfamily member 1, or ERCC1, which are involved in modulation of cell cycle arrest. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, cyclic peptides, nucleic acids, RNAi, antisense nucleic acids, and ribozymes, that modulate cell cycle arrest via modulation of BRCA-1-Associated Protein-1 (BAP-1), Nuclear Protein 95 (NP95), Fanconi anemia group A protein (FANCA), DEAD/H box polypeptide 9 (DDX9), insulin-like growth factor 1 receptor (IGF1R), ubiquitin-conjugating enzyme E2 variant 1 (UBE2V1), aldehyde dehydrogenase, pyruvate kinase, glucose-6-phosphate dehydrogenase, HCDR-3, DEAD/H box polypeptide 21 (DDX21), serine threonine kinase 15 (ARK2), transmembrane 4 superfamily member 1, or ERCC1, as well as to the use of expression profiles and compositions in diagnosis and therapy related to cell cycle regulation and modulation of cellular proliferation, e.g., for treatment of cancer and other diseases of cellular proliferation.
摘要翻译：本发明涉及细胞增殖的调控。更具体地，本发明涉及编码BRCA-1相关蛋白-1（BAP-1），核蛋白95（NP95），Fanconi贫血A组蛋白（FANCA），DEAD / H盒多肽9（DDX9）），胰岛素样生长因子1受体（IGF1R），泛素结合酶E2变体1（UBE2V1），醛脱氢酶，丙酮酸激酶，葡萄糖-6-磷酸脱氢酶，HCDR-3，DEAD / H盒多肽21（DDX21），丝氨酸苏氨酸激酶15（ARK2），跨膜4超家族成员1或ERCC1，其参与调节细胞周期停滞。本发明还涉及用于鉴定和使用包括小分子化学组合物，抗体，肽，环肽，核酸，RNAi，反义核酸和核酶在内的试剂的方法，其通过调节BRCA-1相关的调节细胞周期阻滞蛋白-1（BAP-1），核蛋白95（NP95），Fanconi贫血组A蛋白（FANCA），DEAD / H盒多肽9（DDX9），胰岛素样生长因子1受体（IGF1R），泛素缀合酶 E2变体1（UBE2V1），醛脱氢酶，丙酮酸激酶，葡萄糖-6-磷酸脱氢酶，HCDR-3，DEAD / H盒多肽21（DDX21），丝氨酸苏氨酸激酶15（ARK2），跨膜4超家族成员1或ERCC1 ，以及在与细胞周期调节和细胞增殖调节相关的诊断和治疗中使用表达谱和组合物，例如用于治疗癌症和其他细胞增殖疾病。

12. 发明申请

US20100196511A1 AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER 有权
标题翻译：用于组合治疗的AXL抑制剂用于预防，治疗或管理分子癌
公开(公告)号：US20100196511A1
公开(公告)日：2010-08-05
申请号：US12688746
申请日：2010-01-15
申请人： Yasumichi Hitoshi , Sacha Holland , Donald G. Payan
发明人： Yasumichi Hitoshi , Sacha Holland , Donald G. Payan
IPC分类号： A61K33/24 , A61P35/00 , A61P35/04
CPC分类号： A61K31/502 , A61K31/4196 , A61K33/24 , A61K45/06 , C07D403/04 , C07D403/14 , A61K2300/00
摘要： This invention is directed to methods of preventing, treating or managing cancer, preferably metastatic cancer, in a patient. The methods comprise administering an effective amount of an Axl inhibitor in combination with the administration of an effective amount of one or more chemotherapeutic agents.
摘要翻译：本发明涉及在患者体内预防，治疗或控制癌症，优选转移性癌症的方法。所述方法包括与施用有效量的一种或多种化学治疗剂组合施用有效量的Axl抑制剂。

13. 发明申请

US20090012045A1 Methods of Treating Cell Proliferative Disorders 审中-公开
标题翻译：治疗细胞增殖性疾病的方法
公开(公告)号：US20090012045A1
公开(公告)日：2009-01-08
申请号：US12147387
申请日：2008-06-26
申请人： Yasumichi Hitoshi , Elliott Grossbard , Ankush Argade , Rajinder Singh
发明人： Yasumichi Hitoshi , Elliott Grossbard , Ankush Argade , Rajinder Singh
IPC分类号： A61K31/538 , A61P35/00 , A61K31/5383 , C12N5/00 , A61K31/675 , A61K31/5415
CPC分类号： A61K31/5383 , A61K31/5415 , A61K31/675
摘要： The present disclosure provides methods for the treatment of cell proliferative disorders by administration of a RET kinase inhibitor. Cell proliferative disorders treatable by the methods include, thyroid tumors.
摘要翻译：本公开提供了通过施用RET激酶抑制剂来治疗细胞增殖性疾病的方法。可通过该方法治疗的细胞增殖性疾病包括甲状腺肿瘤。

14. 发明授权

US07358040B2 MRE 11: modulation of cellular proliferation 失效
标题翻译： MRE 11：调节细胞增殖
公开(公告)号：US07358040B2
公开(公告)日：2008-04-15
申请号：US10026331
申请日：2001-12-21
申请人： Yasumichi Hitoshi , Susan Demo , Yonchu Jenkins
发明人： Yasumichi Hitoshi , Susan Demo , Yonchu Jenkins
IPC分类号： C12Q1/00
CPC分类号： C12Q1/34 , G01N33/5011 , G01N33/573 , G01N2333/922 , G01N2500/02
摘要： The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding MRE11, which is a protein involved in modulation of cellular proliferation. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, and ribozymes, that modulate cellular proliferation via modulation of MRE11; as well as to the use of expression profiles and compositions in diagnosis and therapy related to modulation of cellular proliferation.
摘要翻译：本发明涉及细胞增殖的调控。更具体地，本发明涉及编码MRE11的核酸，其是涉及细胞增殖调节的蛋白质。本发明还涉及用于鉴定和使用通过调节MRE11来调节细胞增殖的试剂，包括小分子化学组合物，抗体，肽，环肽，核酸，反义核酸和核酶的方法; 以及在与调节细胞增殖相关的诊断和治疗中使用表达谱和组合物。

15. 发明授权

US06727350B2 Toso 失效
标题翻译：东曹
公开(公告)号：US06727350B2
公开(公告)日：2004-04-27
申请号：US09135238
申请日：1998-08-17
申请人： Garry P. Nolan , Yasumichi Hitoshi
发明人： Garry P. Nolan , Yasumichi Hitoshi
IPC分类号： C07K1600
CPC分类号： C07K14/70503 , A61K38/00
摘要： The present invention is directed to novel polypeptides such as the the Toso protein and related molecuels which have an inhibitory effect on TNF mediated apoptosis and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
摘要翻译：本发明涉及新的多肽，例如Toso蛋白和对TNF介导的细胞凋亡具有抑制作用的相关分子以及编码这些多肽的核酸分子。本文还提供了包含那些核酸序列的载体和宿主细胞，包含与异源多肽序列融合的本发明的多肽的嵌合多肽分子，与本发明的多肽结合的抗体以及本发明的多肽的制备方法发明。

16. 发明申请

US20150087673A1 METHODS FOR USING AND BIOMARKERS FOR AMPK-ACTIVATING COMPOUNDS 审中-公开
标题翻译：用于AMPK激活化合物的方法和生物标志物
公开(公告)号：US20150087673A1
公开(公告)日：2015-03-26
申请号：US14498921
申请日：2014-09-26
申请人： Yasumichi Hitoshi , Yonchu Jenkins , Vadim Markovtsov , Todd Kinsella , Tian-Qiang Sun
发明人： Yasumichi Hitoshi , Yonchu Jenkins , Vadim Markovtsov , Todd Kinsella , Tian-Qiang Sun
IPC分类号： A61K31/4545 , C07D401/14 , A61K45/06 , G01N33/573
CPC分类号： A61K31/4545 , A61K31/4427 , A61K31/501 , A61K31/5377 , A61K45/06 , C07D401/14 , G01N33/573 , G01N2500/04 , A61K2300/00
摘要： Disclosed are methods of using AMPK-activating compounds, for example, in the treatment of cancer and disorders of vascular flow. Also disclosed are biomarkers for AMPK and uses thereof, for example, in the diagnosis and treatment of AMPK-linked disorders. In certain embodiments, the AMPK-activating compounds have the structural formula wherein E, J, T, D1, D2, D3, the ring system denoted by “B”, T, R3, R4, w and x are as described herein.
摘要翻译：公开了使用AMPK活化化合物的方法，例如用于治疗癌症和血管流动障碍。还公开了AMPK的生物标志物及其用途，例如在AMPK相关疾病的诊断和治疗中。在某些实施方案中，AMPK活化化合物具有其结构式，其中E，J，T，D1，D2，D3，由“B”，T，R3，R4，w和x表示的环系统如本文所述。

17. 发明申请

US20120178098A1 WHOLE BLOOD ASSAY FOR MEASURING AMPK ACTIVATION 有权
标题翻译：用于测量AMPK激活的全血测定
公开(公告)号：US20120178098A1
公开(公告)日：2012-07-12
申请号：US13333817
申请日：2011-12-21
申请人： Vadim Markovtsov , Yasumichi Hitoshi
发明人： Vadim Markovtsov , Yasumichi Hitoshi
IPC分类号： G01N21/64 , G01N33/573
CPC分类号： G01N33/573 , G01N33/49 , G01N33/4915 , G01N33/5041 , G01N33/53 , G01N2333/912 , G01N2333/91205 , G01N2800/02
摘要： A method of sample analysis is provided. In certain embodiments, the method comprises: a) labeling cells of a blood sample using an antibody that specifically binds to phospho-AMPK or a phosphorylated target thereof, to produce a labeled sample; and b) measuring antibody binding by a population of blood cells of the labeled sample using flow cytometry. In particular embodiments, the method may further comprise, prior to the labeling step: contacting blood with a test agent ex vivo or in vivo; and comparing the evaluation to results obtained from a reference sample of blood cells.
摘要翻译：提供了样品分析的方法。在某些实施方案中，所述方法包括：a）使用特异性结合磷酸化AMPK或其磷酸化靶标的抗体标记血液样品的细胞，以产生标记的样品; 和b）使用流式细胞术测量标记样品的血细胞群体的抗体结合。在具体实施方案中，该方法还可以包括在标记步骤之前：离体或体内使血液与测试试剂接触; 并将评估与从血细胞的参考样品获得的结果进行比较。

18. 发明授权

US07863222B2 shRNA library 有权
标题翻译： shRNA文库
公开(公告)号：US07863222B2
公开(公告)日：2011-01-04
申请号：US12221325
申请日：2008-08-01
申请人： Donald G. Payan , Mary Shen , Simon Yu , Todd M. Kinsella , Yasumichi Hitoshi
发明人： Donald G. Payan , Mary Shen , Simon Yu , Todd M. Kinsella , Yasumichi Hitoshi
IPC分类号： C40B50/06 , C40B40/08 , C40B30/06 , C40B40/02 , C12P19/34 , A61K49/12
CPC分类号： C12N15/1093 , C12N15/66 , C12P19/34 , C40B40/08 , C40B50/06
摘要： As noted above, certain aspects of this disclosure relate to a library of nucleic acid vectors, as well as a method for making the same. In certain embodiments, the library of nucleic acid vectors comprises: a plurality of nucleic acid molecules of the following formula: S1—R—S2 wherein, in each nucleic acid of the plurality: S1 and S2 are each at least 15 nucleotides in length; S1 and S2 are complementary to each other along their entire length; either S1 or S2 is complementary along its entire length to a sequence in eukaryotic mRNA; and R is a six base recognition site for a restriction endonuclease; and wherein S1 and S2 vary in nucleotide sequence between different members of the plurality. A method for amplifying a circular nucleic acid is also provided.
摘要翻译：如上所述，本公开的某些方面涉及核酸载体文库以及其制备方法。在某些实施方案中，核酸载体文库包含：多个下式的核酸分子：S1-R-S2，其中在多个的每个核酸中，S1和S2的长度各自为至少15个核苷酸; S1和S2沿其整个长度彼此互补; S1或S2在其整个长度上与真核mRNA中的序列互补; R是限制性内切核酸酶的六碱基识别位点; 并且其中S1和S2在多个不同成员之间的核苷酸序列变化。还提供了扩增环状核酸的方法。

19. 发明申请

US20090048214A1 Methods for Treating Renal Tumors Using 2, 4-Pyrimidinediamine Drug and Prodrug Compounds 审中-公开
标题翻译：使用2,4-嘧啶二胺药物和前药化合物治疗肾肿瘤的方法
公开(公告)号：US20090048214A1
公开(公告)日：2009-02-19
申请号：US11940930
申请日：2007-11-15
申请人： Yasumichi Hitoshi , Elliott Grossbard , Ankush Argade , Rajinder Singh , Hui Li , David Carroll , Susan Catalano
发明人： Yasumichi Hitoshi , Elliott Grossbard , Ankush Argade , Rajinder Singh , Hui Li , David Carroll , Susan Catalano
IPC分类号： A61K31/5383 , A61P35/00 , A61K31/675
CPC分类号： A61K31/5365
摘要： The present disclosure provides methods for the inhibiting proliferation of tumor cells, and methods for treating solid tumor cancers in a subject by administration of 2,4-pyrimidinediamine compounds.
摘要翻译：本公开提供了抑制肿瘤细胞增殖的方法，以及通过施用2,4-嘧啶二胺化合物治疗受试者的实体瘤癌症的方法。

20. 发明授权

US07090990B2 NP95: methods of assaying for cell cycle modulators 有权
公开(公告)号：US07090990B2
公开(公告)日：2006-08-15
申请号：US10123568
申请日：2002-04-15
申请人： Yasumichi Hitoshi , Yonchu Jenkins
发明人： Yasumichi Hitoshi , Yonchu Jenkins
IPC分类号： G01N33/574
CPC分类号： G01N33/5091 , C12Q1/6886 , C12Q2600/158 , G01N33/5008 , G01N33/5011 , G01N33/574 , G01N33/6872 , G01N2333/4703
摘要： The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding NP95, which is involved in modulation of cell cycle arrest. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, cyclic peptides, nucleic acids, RNAi, antisense nucleic acids, and ribozymes, that modulate cell cycle arrest via modulation of NP95; as well as to the use of expression profiles and compositions in diagnosis and therapy related to cell cycle regulation and modulation of cellular proliferation, e.g., for treatment of cancer and other diseases of cellular proliferation.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式